{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-022979","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-05-27T20:01:34+00:00","discovered_at":"2026-05-27T20:03:00.329169+00:00","generated_at":"2026-05-27T20:06:43.574075+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026","bullets":["FDA accepted NDA with Priority Review for BBP-418 to treat LGMD2I/R9; PDUFA target action date November 27, 2026.","No advisory committee meeting currently planned for the application.","Phase 3 FORTIFY trial met all primary and secondary endpoints; treated patients improved while placebo declined.","If approved, BBP-418 would be first and only therapy for LGMD2I/R9 and first approved treatment for any form of LGMD.","BridgeBio plans to start studies in patients under 12 years and in LGMD2M/R13 and LGMD2U/R20."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-022979","json":"https://secwatch.observer/filing/0001140361-26-022979.json","markdown":"https://secwatch.observer/filing/0001140361-26-022979.md","text":"https://secwatch.observer/filing/0001140361-26-022979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/0001140361-26-022979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T20:06:43.574075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001104659-26-068659","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-06-01T13:15:32+00:00","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068659","json":"https://secwatch.observer/filing/0001104659-26-068659.json","markdown":"https://secwatch.observer/filing/0001104659-26-068659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/0001104659-26-068659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062172","ticker":"RR","company_name":"RICHTECH ROBOTICS INC.","filed_at":"2026-05-28T20:49:32+00:00","headline":"Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062172","json":"https://secwatch.observer/filing/0001213900-26-062172.json","markdown":"https://secwatch.observer/filing/0001213900-26-062172.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/ea0292546-8k_richtech.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-065992","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-05-26T11:15:41+00:00","headline":"FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-065992","json":"https://secwatch.observer/filing/0001104659-26-065992.json","markdown":"https://secwatch.observer/filing/0001104659-26-065992.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/0001104659-26-065992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-060667","ticker":"LRHC","company_name":"La Rosa Holdings Corp.","filed_at":"2026-05-22T21:20:15+00:00","headline":"La Rosa Holdings receives Nasdaq deficiency notice for late 10-K and 10-Q filings","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060667","json":"https://secwatch.observer/filing/0001213900-26-060667.json","markdown":"https://secwatch.observer/filing/0001213900-26-060667.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1879403/000121390026060667/0001213900-26-060667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1879403/000121390026060667/ea0291964-8k_larosa.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-064861","ticker":"RGTI","company_name":"Rigetti Computing, Inc.","filed_at":"2026-05-21T11:30:49+00:00","headline":"Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity","event_type":"regulatory","sec_items":["3.02","8.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064861","json":"https://secwatch.observer/filing/0001104659-26-064861.json","markdown":"https://secwatch.observer/filing/0001104659-26-064861.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/0001104659-26-064861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/tm2615300d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-024659","ticker":"NNE","company_name":"Nano Nuclear Energy Inc.","filed_at":"2026-05-20T21:10:43+00:00","headline":"NRC accepts Nano Nuclear's construction permit application for KRONOS MMR at Univ. of Illinois","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024659","json":"https://secwatch.observer/filing/0001493152-26-024659.json","markdown":"https://secwatch.observer/filing/0001493152-26-024659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1923891/000149315226024659/0001493152-26-024659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1923891/000149315226024659/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001651308-26-000012","ticker":"ONC","company_name":"BeOne Medicines Ltd.","filed_at":"2026-05-15T20:08:07+00:00","headline":"BeOne Medicines gets FDA accelerated approval for BEQALZI (sonrotoclax) in R/R MCL","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-26-000012","json":"https://secwatch.observer/filing/0001651308-26-000012.json","markdown":"https://secwatch.observer/filing/0001651308-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000012/0001651308-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000012/bgne-20260513.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-021504","ticker":"SSTK","company_name":"Shutterstock, Inc.","filed_at":"2026-05-15T12:53:14+00:00","headline":"UK CMA issues final Phase 2 report on Shutterstock-Getty merger","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-021504","json":"https://secwatch.observer/filing/0001140361-26-021504.json","markdown":"https://secwatch.observer/filing/0001140361-26-021504.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549346/000114036126021504/0001140361-26-021504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549346/000114036126021504/ef20073673_8k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}